NASDAQ · Biotechnology

TNXP (TNXP) Stock

$10.09 +6.10% NASDAQ: TNXP Healthcare

Valuation

MetricValue
Price$10.09
Market Cap$160.84M
P/E Ratio-1.00
P/B Ratio0.95
P/S Ratio13.17
EPS (TTM)$-14.57
52-Week High$69.97
52-Week Low$9.88
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-50.61%
ROA-44.77%
ROCE-51.43%
Gross Margin-969.23%
Operating Margin-969.23%
Net Margin-8.40%
Debt/Equity0.01
Current Ratio7.39

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$8.0M$10.0M$13.0M
Operating Profit$-92.0M$-112.0M$-118.0M$-137.0M$-126.0M
Net Profit$-92.0M$-110.0M$-117.0M$-130.0M$-124.0M
EPS$-163968.00$-811.68$-6368.84$-176.60$-14.57
Op Margin——-1523.9%-1354.3%-959.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$241.0M$226.0M$154.0M$163.0M$277.0M
Total Liabilities$22.0M$19.0M$49.0M$23.0M$32.0M
Cash$179.0M$120.0M$25.0M$99.0M$208.0M
Borrowings$1.0M$1.0M$10.0M$5.0M$1.0M

Latest News

Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models GlobeNewswire · Jul 15, 2026 Tonix Expands TONMYA Medicare Coverage with New Payer Agreement (TNXP) InvestorsHub · Jul 13, 2026 Tonix Pharmaceuticals Reaches Medicare Coverage Deal for Fibromyalgia Treatment MT Newswires · Jul 13, 2026 Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA® GlobeNewswire · Jul 13, 2026 Tonix Pharmaceuticals Advances TNX-102 SL Into Phase 2 MDD Study MT Newswires · Jun 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-76.0M$-98.0M$-102.0M$-61.0M$-100.0M
Investing Cash Flow$-71.0M$-96.0M$-37.0M$0$-8.0M
Financing Cash Flow$0$0$9.0M$-3.0M$-14.0M
Net Cash Flow$102.0M$-58.0M$-95.0M$74.0M$110.0M
Free Cash Flow$-111.0M$-146.0M$-110.0M$-61.0M$-103.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-57.39%
Quick Ratio6.86
Interest Coverage—
Return 1Y-74.15%
Return 3Y-99.80%
Return 5Y-100.00%

Ownership

Insiders Held0.14%
Institutions Held45.81%
Institutions Float Held45.88%
Institutional HolderSharesReport Date
Blackrock Inc.968,1772026-03-31
Vanguard Capital Management LLC518,6502026-03-31
Citadel Advisors Llc468,7122026-03-31
Jones Hill Capital LP452,1162026-03-31
Geode Capital Management, LLC313,2912026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
APLTApplied Therapeutics, Inc. $0.10 +0.00% -0.24 $14.86M 0.00%
AVTX $18.97 +2.87% -2.79 $214.25M 0.00%
ELDN $3.69 +6.65% -4.85 $284.82M 0.00%
ELTXElicio Therapeutics, Inc. $3.01 +0.17% -1.27 $57.29M 0.00%
FATE $2.31 -0.43% -1.62 $269.25M 0.00%

About TNXP

TNXP is led by CEO Seth Lederman, employs 81 people, headquartered in US, publicly traded since 2012.

TNXP stock trades at $10.09 with a market capitalization of $160.84M. The stock is valued at a price-to-earnings (P/E) ratio of -1.00, price-to-book of 0.95, price-to-sales of 13.17. Over the past 52 weeks the stock has ranged between $9.88 and $69.97, and currently trades 85.6% below its 52-week high.

On profitability, TNXP generates a return on equity (ROE) of -50.61%, return on capital employed of -51.43%, an operating margin of -969.23%, a net profit margin of -8.40%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides